Ellipses updates clinicians at Asco on clinical trial programmes

Ellipses Pharma (“Ellipses”), a global company drug development company focused on accelerating innovative cancer medicines and treatments, today announces its leadership team will attend the forthcoming American Society of Oncology (ASCO) conference in Chicago where they will brief clinicians on the progress of clinical and pre-clinical programmes which are showing ‘significant promise’.

The Ellipses team, led by CEO Dr Rajan Jethwa and Professor Tobi Arkenau, Global Head of Drug Development and Chief Medical Officer, will brief around 100 ASCO  delegates at a special event on the status of a range of programmes under development within the Ellipses asset portfolio.  These include trials of EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia (AML), EP0062, a selective androgen receptor modulator currently under development for the treatment of advanced breast cancer and EP0031, a next generation selective RET Inhibitor. A closed session will also be held with leading oncologists on the current and future RET inhibitor landscape.

Dr Rajan Jethwa commented:” We are delighted to have the opportunity to brief leading oncologists from around the world attending ASCO on programmes within our portfolio that are showing significant promise as well as shining a light on exciting developments on the RET inhibitor landscape.”

Prof Tobi Arkenau commented: “We are pleased to update those with an interest in our drug development programmes and the ASCO conference provides the ideal forum in which to reflect our progress. The assets we shall be discussing are currently at various stages in Phase 1/2 trials and results have been very encouraging. These assets have the potential to provide significant new treatments for cancer patients and we look forward to taking these assets to the next stage of clinical development.”

Professor Sir Chris Evans, OBE, chairman of Ellipses, commented: “ I am delighted that Ellipses will be attending ASCO with such a strong team, led by Rajan and Tobi, which will be revealing to leading oncologists the exciting developments in our clinical programmes.”

About EP0042

EP0042 is being developed as a new potential treatment to combat acquired resistance to FLT3 inhibitors in patients with AML. Around one third of patients with AML are diagnosed with FLT3-mutations, which are associated with a higher risk of relapse and poor clinical outcome. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia (AML). The FDA grants ODD based on review of promising early clinical data from investigational treatments for rare diseases,

About EP0062

Vosilasarm (EP0062) is an orally available non-steroidal SARM currently being investigated in an adaptive phase 1/2 dose optimisation study in patients with advances ER+/AR+ breast cancer. This study is designed to further extend the evaluation of vosilasarm as a potential therapy for AR+/HER2–/ER+ advanced breast cancer, with the primary aim of identifying a recommended phase 2 dose (RP2D). Recruitment has commenced and the study will recruit up to 130 patients globally.

About EP0031

Developed in partnership with Sichuan Kelun-Biotech Pharmaceutical Co., Ltd (Kelun-Biotech), EP0031, known as A400 when in conjunction with Kelun-Biotech’s ongoing regional development, is the subject of a global, modular phase 1/2 trial to evaluate the safety, tolerability and efficacy of EP0031 in patients with advanced RET-altered tumours and has been under clinical investigation in China for NSCLC and thyroid cancers. Kelun-Biotech is reporting its clinical data on dose expansion at the ASCO conference on June 5, 2023.

About Ellipses Pharma Limited

Ellipses Pharma is a global drug development company headquartered in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection, the expertise of a Scientific Affairs Group which comprises 200 plus leading oncologists and an uninterrupted funding flow to minimise the time it takes to advance lead products through clinical trials and reach patients.

For more information contact us: media@ellipses.life